<DOC>
	<DOCNO>NCT00052832</DOCNO>
	<brief_summary>RATIONALE : Doxercalciferol may improve low blood cell count decrease need blood transfusion may effective treatment myelodysplastic syndrome chronic myelomonocytic leukemia . PURPOSE : Phase II trial study effectiveness doxercalciferol treat patient myelodysplastic syndrome chronic myelomonocytic leukemia .</brief_summary>
	<brief_title>Doxercalciferol Treating Patients With Myelodysplastic Syndrome Chronic Myelomonocytic Leukemia</brief_title>
	<detailed_description>OBJECTIVES : - Determine response rate patient myelodysplastic syndrome chronic myelomonocytic leukemia treat doxercalciferol . - Determine toxicity profile drug patient . - Determine time progression overall survival patient treated drug . OUTLINE : Patients receive oral doxercalciferol daily 12 week . Treatment continue absence disease progression unacceptable toxicity . PROJECTED ACCRUAL : Approximately 41 patient accrue study .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Chronic</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Myelodysplastic-Myeloproliferative Diseases</mesh_term>
	<mesh_term>1 alpha-hydroxyergocalciferol</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Morphologically cytogenetically confirm myelodysplastic syndrome chronic myelomonocytic leukemia No 20 % blast bone marrow biopsy Must meet least 1 follow criterion : Anemia Hemoglobin le 11 g/dL 2month period Thrombocytopenia Neutropenia PATIENT CHARACTERISTICS : Age 18 Performance status ECOG 02 Life expectancy Not specify Hematopoietic See Disease Characteristics Hepatic ALT AST less 1.5 time upper limit normal Bilirubin le 3 mg/dL Albumin great 3.0 g/dL Renal Creatinine clearance great 50 mL/min No history hypercalcemia No renal stone within past 5 year Cardiovascular No clinically significant heart failure No uncontrolled hypertension Pulmonary No clinically significant pulmonary failure Other Not pregnant Fertile patient must use effective contraception 6 month study PRIOR CONCURRENT THERAPY : Biologic therapy At least 4 week since prior growth factor cytokine therapy Chemotherapy At least 8 week since prior cytotoxic chemotherapy Endocrine therapy Not specify Radiotherapy Not specify Surgery Not specify Other Concurrent transfusion support allow</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>chronic myelomonocytic leukemia</keyword>
	<keyword>previously treat myelodysplastic syndrome</keyword>
	<keyword>secondary myelodysplastic syndrome</keyword>
	<keyword>de novo myelodysplastic syndrome</keyword>
	<keyword>atypical chronic myeloid leukemia</keyword>
	<keyword>myelodysplastic/myeloproliferative disease , unclassifiable</keyword>
</DOC>